Mentice AB (publ) receives an order of 1,1 million USD for simulation solutions from Beijing Huanya Zhitong on behalf of the Chinese Medical Education Association.
GOTHENBURG, Sweden, Dec. 20, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Beijing Huanya Zhitong, Beijing, China, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of 1,1 million USD. For more information, please contact:Göran Malmberg, CEO, MenticeE-post: goran.malmberg@mentice.comUS Mobile. +1 (312) 860...
Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination
Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a...
Shen Peng Awarded Charitable Entrepreneur of For Good Awards 2022
BEIJING, Dec. 19, 2022 /PRNewswire/ -- The annual conference of For Good Awards of China Social Enterprise and Impact Investment Forum declared the winners of For Good Awards 2022. Mr. Peng Shen, Founder and CEO of Waterdrop, was awarded one of the Top 10 Charitable Entrepreneurs of For Good Awards 2022. For Good Awards 2022 is sponsored by...
Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board
SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board. He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific...
Health and Hydrogen launches one of the first medical-grade Molecular Hydrogen Inhalation Machine HAH-301
GURGAON, India, Dec. 19, 2022 /PRNewswire/ -- Molecular Hydrogen Inhalation therapy is now extensively used for its many health benefits, such as reducing inflammation, improving cellular function, and protecting against oxidative stress. Health And Hydrogen recently launched a revolutionary, easy-to-use medical-grade molecular hydrogen inhalation HAH- 301 device to provide patients with these benefits. This device can deliver a high flow rate...
Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON
WUHAN, China and SAN DIEGO, Dec. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on the in-vivo gene replacement therapy NFS-02 (rAAV2-ND1), for the treatment of Leber hereditary optic neuropathy (LHON) associated with ND1...
SeekIn Receives CE-IVD Mark Approval for PanCanSeek® Cancer Mutation Detection Kit
First-of-its-kind one-for-all cancer mutation detection test SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit and is now ready to launch this test in European Union and other countries that recognize CE-IVD Mark. Cancer is a...
China and ASEAN Deepened Exchanges and Cooperation on Traditional Medicine
BEIJING, Dec. 19, 2022 /PRNewswire/ -- A report from CRIOnline: From December 11 to 13, the 7th China-ASEAN Forum on Traditional Medicine was held in Fangchenggang City, Guangxi, China. China-ASEAN Forum on Traditional Medicine is held every two years. With the theme of "Seizing RCEP Opportunities to Promote High-quality Development of Traditional Medicine", the 7th Forum held discussions focused...
GenFleet Therapeutics and Merck Enter into Trial Collaboration to Initiate Study Investigating Combination Therapy of GFH925 (KRAS G12C inhibitor) and ERBITUX® (cetuximab)
SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck to start a clinical study of the combination therapy of GFH925 with ERBITUX® (cetuximab) as a potential frontline treatment among NSCLC patients harboring KRAS...
Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives
--The issue date of the patent will be January 3, 2023 by the United States Patent and Trademark Office (USPTO). The patent number is 11,541,071 -- The issued patent covers ASC10 and its derivatives, and their uses to treat virus infections including SARS-CoV-2, monkeypox virus and respiratory syncytial virus (RSV) -- Ascletis is the first Chinese biotech company...
